52nd week of 2020 patent applcation highlights part 9 |
Patent application number | Title | Published |
20200397691 | NICOTINE MOUTH SPRAY - The invention relates to a liquid nicotine mouth spray formulation for oral mucosal delivery and fast onset nicotine craving relief, the mouth spray formulation being designed to adhere to the oral mucosa, and the mouth spray formulation being designed to utilize free nicotine base as both a source of nicotine and a source of pH regulating agent, wherein the mouth spray formulation does not contain any further pH regulating agent other than said free nicotine base. | 2020-12-24 |
20200397692 | SYSTEM FOR PROVIDING BIRTH CONTROL - The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles. | 2020-12-24 |
20200397693 | COMPOSITIONS COMPRISING CANNABIS SATIVA OIL AND USES THEREOF - The subject invention provides topical skin moisturizing compositions comprising | 2020-12-24 |
20200397694 | EMULSIFIED GEL COMPOSITION - The present invention provides an emulsified gel composition comprising a physiologically active substance, water, a gelling agent, an anti-peeling agent, and a surfactant having an HLB value of 18 to 20, in which the gelling agent is a nonionic water-soluble polymer, and the anti-peeling agent is one or more compounds selected from the group consisting of sucrose, sorbitol, polyethylene glycol, glycerin, a (meth)acrylic-based polymer compound, and a polyoxyethylene hydrogenated castor oil. | 2020-12-24 |
20200397695 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES - Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition. | 2020-12-24 |
20200397696 | APPARATUS, SYSTEMS, AND METHODS FOR CONTINUOUS MANUFACTURING OF NANOMATERIALS AND HIGH PURITY CHEMICALS - A method for continuously processing at least two liquid feed streams is provided. A system for continuously processing at least two liquid feed streams is also provided. | 2020-12-24 |
20200397697 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF - Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTPβ. Further disclosed are formulations to increase the efficacy of the compounds that activate Tie-2 and inhibit HPTPβ. | 2020-12-24 |
20200397698 | FUSOGENIC LIPOSOME-COATED POROUS SILICON NANOPARTICLES - The disclosure describes a fusogenic liposome-coated porous silicon nanoparticles for high loading efficiency of anionic payloads (small molecules, dyes, nucleic acids), and for non-endocytic delivery of hydrophilic and lipophilic payloads by membrane fusion. The liposome coating can be further modified with targeting peptides or antibodies via covalent binding chemistry between the ligands and functionalized poly(ethylene glycol). The surface moieties can be transferred to the cellular membrane surface by fusogenic uptake. The composition of the disclosure can be applied in the treatment of diseases by delivering entrapped/encapsulated payloads. | 2020-12-24 |
20200397699 | ZINC MELOXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND PROCESSES FOR MAKING THE SAME - Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided. | 2020-12-24 |
20200397700 | GRANULAR COMPOSITION, PRODUCTION METHOD FOR GRANULAR COMPOSITION, AND DISSOLUTION PROPERTY IMPROVEMENT METHOD FOR GRANULAR COMPOSITION - A production method for a granular composition in which the dissolution property of 2-{4-[N-(5,6-diphenylpyradin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is improved is provided. | 2020-12-24 |
20200397701 | Drug delivery system and method for the treatment of neuro-degenerative disease - Embodiments of the present invention are directed to drug delivery systems, dosage forms and methods for the intranasal administration of Bryostatins for the treatment of neuro-degenerative diseases. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down syndrome and Alzheimer's disease. | 2020-12-24 |
20200397702 | PHARMACEUTICAL COMPOSITIONS - Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof. | 2020-12-24 |
20200397703 | PACKAGE AND METHOD FOR PRODUCING THE SAME - There is provided a package wherein a pharmaceutical composition containing a saccharide-degrading enzyme is contained in a container, whereby reduction in titer caused by a low amount of enzyme is suppressed. A package comprising a pharmaceutical composition and a container, wherein the pharmaceutical composition is a lyophilized preparation containing a saccharide-degrading enzyme as an active ingredient, and the container contains the pharmaceutical composition, the inner surface of the container comprising at least one material selected from the group consisting of fine ceramics, silicone resins and fluorine resins. | 2020-12-24 |
20200397705 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES - Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form. | 2020-12-24 |
20200397706 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES - Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form. | 2020-12-24 |
20200397707 | GEL PRODUCT INSTANT-DISSOLVING BLOCK AND PREPARATION METHOD THEREOF - A method for preparing a gel product instant-dissolving block includes: adding water into a raw material to dissolve the raw material and carrying out concentrating to obtain a gel solution; carrying out a drying treatment on the gel solution to obtain an irregular cellular gel body; grinding the gel body and carrying out screening to obtain gel powder with a particle size being equal to or larger than 80 meshes; moistening the gel powder with 85 to 95% alcohol and carrying out compression at a compression ratio of 30% to 60% to obtain a block, thereby obtaining the gel product instant-dissolving block. The gel product instant-dissolving block of the present invention has a loose pore structure at the inside, has a high superficial area/volume ratio and has a product density of 0.4 to 0.8 g/cm | 2020-12-24 |
20200397708 | PHARMACEUTICAL DOSAGE FORM FOR APPLICATION TO MUCOUS MEMBRANES - The present invention relates to a pharmaceutical dosage form for application to a mucous membrane, in particular to a buccal, intestinal, rectal or vaginal mucous membrane, comprising at least one sheet like, in particular film shaped, foil shaped or wafer shaped preparation comprising the active pharmaceutical ingredient, a release mechanism, and a trigger mechanism, wherein the trigger mechanism is adapted to trigger, at a predetermined site of action, in particular of the gastrointestinal tract, of the rectum or of the vagina, the release of the sheet like preparation by the release mechanism. | 2020-12-24 |
20200397709 | INSTANT RELEASE PHARMACEUTICAL PREPARATION OF ANTICOAGULANT AND PREPARATION METHOD THEREFOR - The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 μm. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (C | 2020-12-24 |
20200397710 | MAGNETOELECTRIC NANOPARTICLES FOR ACUPUNCTURE TREATMENT OF DISEASES - The present invention introduces magnetoelectric nanoparticles into acupuncture points that interact with cells, receptors, or molecules in the presence of an applied magnetic field to treat various disorders. | 2020-12-24 |
20200397711 | MICROPARTICLE COMPOSITIONS FOR TREATMENT OF INFECTION OR DISEASE, METHODS OF MAKING THE SAME, AND METHODS OF TREATING SUBJECTS WITH MICROPARTICLE COMPOSITIONS - Provided are microparticle compositions, methods of making the compositions, and methods of treating a subject with the present microparticle compositions by administering an effective amount of the microparticle composition for treating an infection or disease, to a subject in need thereof. The present microparticle compositions may include microparticles of essential oils, herbs, and/or supplements. By way of non-limiting example, the microparticle compositions may be particularly effective in the treatment of a Lyme tick borne illness related infection or disease, or a coronavirus, such as COVID-19. Also included are kits that include one or more of the present microparticle compositions and/or one or more components of the present compositions, and optionally one or more components, such as a device to aid in the delivery of the composition and/or instructions for administration. | 2020-12-24 |
20200397712 | NOVEL RNAi MOLECULE DELIVERY PLATFORM BASED ON SINGLE-siRNA AND shRNA NANOCAPSULES - Novel siRNA and shRNA nanocapsules and delivery methods are disclosed herein. These siRNA and shRNA nanocapsules and delivery methods are highly robust and effective. This invention provides a platform for RNAi delivery with low toxicity and long intracellular half-life for practical therapeutic applications. | 2020-12-24 |
20200397713 | CHLOROQUINE GEL AND PREPARATION METHOD AND APPLICATION THEREOF - A chloroquine gel and a preparation method and application thereof. A chloroquine nanosphere includes a water-soluble nanosphere carrier, and chloroquine or a chloroquine derivative, wherein a mass ratio of the chloroquine or the chloroquine derivative to the water-soluble nanosphere carrier is no more than 1:3. | 2020-12-24 |
20200397714 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE ACRYLIC HYBRID POLYMER - The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone acrylic hybrid polymer. | 2020-12-24 |
20200397715 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING AT LEAST ONE ADDITIVE - The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one polymer and at least additive. | 2020-12-24 |
20200397716 | TRANSDERMAL PENETRANT FORMULATIONS CONTAINING CANNABIDIOL - Disclosed herein is a transdermal delivery formulation for transdermal delivery of a Cannabidiol, with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides, ii. glucose, and iii. one or more fatty acids; b) water in an amount less than about 50% w/w, a Cannabidiol with or within one or more additional active agents. | 2020-12-24 |
20200397717 | Hemp Oil / Magnesium Preparation for Cognitive-Enhancement and Reduction of Stress and Inflammation - Novel neuroprotective preparations of hemp oil and magnesium are disclosed herein. Antioxidant and anti-inflammatory activity of hemp oil (containing a broad-spectrum of beneficial phytochemicals) are combined with magnesium and has been found to reduce oxidative stress, upregulation of antioxidant enzyme systems, and the mitigation of NMDA-receptor hyperactivity. The synergistic effects of hemp oil and bioavailable magnesium are utilized to improve cognitive function, mood, stress tolerance, and reduce oxidative stress and inflammation. A highly-efficacious, lipophilic, trans-mucosal, delivery system is included to provide exceptional bioavailability of a palatable and convenient intra-oral, or topical, anti-inflammatory, neurotrophic, and neuroprotective preparation. Additionally, methods of use are described, allowing for effective, safe, and convenient use for general (public) and clinical use, in both humans and animals. | 2020-12-24 |
20200397718 | USE OF HYDROXYTYROSOL ACETATE IN IMPROVING FUNCTION OF AORTIC ENDOTHELIAL CELL - The present disclosure discloses use of hydroxytyrosol acetate in preparation of a medicament for improving aortic endothelial cell function. The hydroxytyrosol acetate is capable of inhibiting an inflammation of aortic endothelial cells caused by a saturated fatty acid, reducing mRNA levels corresponding to matrix metalloproteinase-1 (MMP-1), intercellular adhesion molecule-1 (ICAM-1) and plasma plasminogen activator inhibitor-1 (PAI-1) in aortic endothelial cells and protecting mitochondria from being damaged by inflammation of aortic endothelial cells caused by a saturated fatty acid, preventing the occurrence and development of atherosclerosis by anti-inflammatory and protecting mitochondrial function. | 2020-12-24 |
20200397719 | SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF - This application describes a compound represented by Formula (I): | 2020-12-24 |
20200397720 | METHOD AND FORMULATION FOR TREATMENT OF WOUNDS BY NEW TISSUE REGENERATION WITH REDUCED TRAUMA AND SCAR TISSUE FORMATION - The present teachings are directed to a method of promoting new tissue regeneration and wound healing in a mammal by inhibiting production of at least one of inflammatory cells, neutrophils, macrophages, and leukocyte lineages in a wound area, limiting inflammation of the wound area, and decreasing degradation of platelets, thereby modulating the coagulation process and formation of a clot by application of a formulation containing a steroid, a mixture of at least two antibiotics, and a vitamin A derivative. The method further includes applying the formation to a wound thereby reducing bleeding from any opened blood vessels in the wound by vasoconstriction, and preventing formation of a clot within the wound. The disclosed healing method reduces the need for stitches or sutures, minimizes scarring, and reduces patient trauma by quickly reducing bleeding, pain and inflammation. Also disclosed is a healing formulation composed of a steroid, a mixture of at least two antibiotics, and a vitamin A derivative. | 2020-12-24 |
20200397721 | Methods of Treating or Preventing an Attention Disorder, Cognitive Disorder, and/or Dementia Associated with a Neurodegenerative Disorder - The present invention provides a method of treating or preventing an attention and/or cognitive disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. The present invention further provides a method of treating or preventing dementia associated with a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a compound useful within the invention. | 2020-12-24 |
20200397722 | EPINEPHRINE SPRAY FORMULATIONS - Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment. | 2020-12-24 |
20200397723 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2020-12-24 |
20200397724 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2020-12-24 |
20200397725 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN - The present invention relates to C5aR inhibitor compounds, preferably C5aR noncompetitive allosteric inhibitors, useful in the treatment and/or prevention of chemotherapy-induced iatrogenic pain (CIIP). | 2020-12-24 |
20200397726 | DISULFIRAM AND METAL SALT STAGGERED ORAL DOSING REGIMEN AND STAGGERED-RELEASE ORAL UNIT DOSAGE FORMS - This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion. | 2020-12-24 |
20200397727 | DRUG VEHICLE COMPOSITIONS AND METHODS OF USE THEREOF - The invention is directed to a topical lidocaine gel composition comprising lidocaine or a salt thereof, one or more nonionic surfactants, a polyethylene glycol, mannitol, magnesium chloride, sodium chloride and carboxymethyl cellulose. The invention is further directed to a method of inducing local anesthesia in an eye of a patient comprising topically applying compositions of the present invention to the eye of the patient. | 2020-12-24 |
20200397728 | PHARMACEUTICAL FORMULATION FOR CARGLUMIC ACID - The present disclosure relates to a pharmaceutical formulation comprising carglumic acid, tromethamine, and one or more pharmaceutically acceptable excipients. The formulation of the present disclosure can be useful for treating hyperammonaemia | 2020-12-24 |
20200397729 | TRISODIUM CITRATE COMPOSITIONS HAVING ENHANCED UPTAKE ACROSS DIGESTIVE MUCOSA - The present invention relates to formulations of certain amino acids, peptides and similar molecules in combination with trisodium citrate exhibiting improved bioavailability and enhanced uptake across digestive mucosa. The present invention relates particularly to formulation of trisodium citrate in combinations with leucine, iso-leucine, valine, arginine, sarcosine, glutathione, carnosine, glucosamine, creatine, protein hydrolysates and/or gamma-aminobutyric acid exhibiting improved uptake across digestive mucosa. More particularly, the improved uptake across digestive mucosa takes place across intestinal, esophageal and/or stomach mucosa. | 2020-12-24 |
20200397730 | Continuous Administration of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors and Compositions for Same - Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods. | 2020-12-24 |
20200397731 | MEDICINAL COMPOSITION FOR PREVENTING OR TREATING SECONDARY HYPERPARATHYROIDISM UNDER MAINTENANCE DIALYSIS - A medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis, said medicinal composition comprising 3-{[(2S)-2-amino-2-carboxyethyl]carmaboylamino}-5-chloro-4-methylbenzenesulfonic acid or a pharmaceutically acceptable salt thereof, or a solvate of the same which is to be administered by a predefined route in a predefined dosage. According to the present invention, it is possible to provide a prophylactic or therapeutic agent for secondary hyperparathyroidism under maintenance dialysis, said agent showing reduced side effects or no significant accumulation. This medicinal agent allows easy administration management and has a high safety compared with conventional products. | 2020-12-24 |
20200397732 | METHODS AND COMPOSITIONS FOR IDENTIFICATION AND MODULATION OF MICROBIOME BIOCHEMICAL PATHWAYS TO ALTER PHENOTYPE - Provided, in part, are methods, compositions, and systems are provided for detecting one or more repellent-generating enzymatic pathways by characterizing the skin microbiomes and metabolomes of populations of individuals both naturally resistant and highly prone to bites from blood sucking arthropods, determining the microbial taxa (and their associated metabolic pathways) most associated with insect repellency and targeting/activating those pathways with molecular substrates that, when metabolized, will give rise, in situ, to repellent molecules and can promote a shift to a more naturally repellent microbiome composition. | 2020-12-24 |
20200397733 | COMPOSITION FOR PROMOTING SKELETAL MUSCLE ACTIVITY VIA INDUCTION OF MITOCHONDRIAL BIOGENESIS COMPRISING OF AZELAIC ACID AS AN ACTIVE INGREDIENT - A composition for promoting mitochondrial biogenesis includes an effective amount of an azelaic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Azelaic acid, which is a compound mainly contained in cereals and natural products has the advantage of no or little side effects, and induces mitochondrial autophagy and mitochondrial DNA synthesis in cells, thereby having activity of increasing mitochondrial density. Therefore, azelaic acid can be used for the treatment of mitochondrial dysfunction-associated disease caused by the failure of homeostasis control of the mitochondria, for example, mitochondrial activity or the decrease in the number of mitochondria. In addition, azelaic acid can be provided to reinforce a muscle function and prevent muscle aging using the activity, and to be effectively used in a food material, a pharmaceutical composition, and health functional foods for treating mitochondrial dysfunction-associated disease, reinforcing a muscle function, or preventing muscle aging. | 2020-12-24 |
20200397734 | PURIFIED COMPOSITIONS OF POLYUNSATURATED FATTY ACIDS, THEIR PREPARATION METHOD AND THEIR USE - The present invention refers to new purified compositions of long chain polyunsaturated fatty acids, or their salts or esters, characterized by being essentially free from other usually present—but structurally different—components, such as furan fatty acids, phytanic and pristanic acids, squalene, and some oligomers, as well as several “persistent” environmental pollutants, such as polychlorinated dibenzo-dioxins and polychlorinated dibenzo-furans, polychlorinated biphenyls, polybrominated diphenyl-ethers, polycyclic aromatic hydrocarbons, and others, which are also usually present and extremely toxic. The invention also refers to the purification method to obtain said compositions and the use thereof as food, food for special medical use, food and diet supplement, and drug. | 2020-12-24 |
20200397735 | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 2020-12-24 |
20200397736 | COMPOSITIONS AND METHODS FOR WEIGHT LOSS MAINTENANCE - Compositions and methods for inducing weight loss, fat loss, maintaining weight or fat loss, suppressing appetite, reducing calorie intake, reducing weight gain, decreasing feed efficiency, increasing metabolic inefficiency, increasing energy expenditure, increasing thermogenesis and/or resetting metabolic set are disclosed. The compositions have a therapeutically effective amount of a ketogenic supplement, e.g., a ketone diesters, such as R,S 1,3-butanediol diacetoacetate. Compositions of one or more beta-hydroxybutyrate, beta-hydroxybutyrate salt, and medium chain triglycerides are also disclosed. | 2020-12-24 |
20200397737 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF ACUTE RADIATION SYNDROME AND OTHER RADIATION EXPOSURE - In one aspect, use of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG) for treating or preventing acute radiation syndrome is provided. | 2020-12-24 |
20200397738 | METHODS FOR TREATING CANCER AND PROTECTING RENEWABLE TISSUES - Provided are methods for treating a subject having or at risk of developing cancer by administering a compound that preserves p53. Also disclosed are methods for protecting renewable tissues by administering a compound that stabilizes EZH2. | 2020-12-24 |
20200397739 | SYNERGISTIC COMPOSITION OF VITAMIN C AND VITAMIN K1, AND COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER - The present invention relates to a pharmaceutical composition comprising vitamin C, or pharmaceutically acceptable salt, solvate or hydrate thereof, in combination with vitamin K1, or pharmaceutically acceptable salt, solvate or hydrate thereof, and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and a pharmaceutically acceptable carrier. Further provided herein is the method of treating, managing, or preventing cancer in human comprising administering a predetermined dosage of pharmaceutical composition comprising Vitamin C or pharmaceutically acceptable salts thereof and Vitamin K1 or a pharmaceutically acceptable salt thereof and may or may not include chromium, or a pharmaceutically acceptable salt, solvate, or hydrate thereof at a predetermined time. | 2020-12-24 |
20200397740 | 2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE FOR USE ON TREATING CANCER - The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof. | 2020-12-24 |
20200397741 | MELATONIN AGONIST TREATMENT - Melatonin Agonist, MA-1, is administered at effective doses. | 2020-12-24 |
20200397742 | COMPOSITIONS AND METHODS FOR TREATING AN INFECTION - The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more antimicrobial agents such as mupirocin. | 2020-12-24 |
20200397743 | CANNABIONID AND CANNABIS-BASED COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE GASTROINTESTINAL TRACT - The invention provides compositions and methods for treating inflammatory condition of the gastrointestinal (GI) tract, specifically those related to Inflammatory Bowel Disease (IDB). Compositions according to the invention due to their specific content of cannabinoids and methods comprising specific modes of administration thereof are particularly applicable to the treatment of the two major IDBs, Crohn's disease and colitis. | 2020-12-24 |
20200397744 | COMPOSITIONS COMPRISING CO-CRYSTALS OF STILBENOIDS AND CANNABINOIDS - A composition for oral administration comprising a cannabinoid in combination with a stilbenoid or derivative thereof and a solubility enhancing agent is described. Oral dosage forms, in the form of dissolvable tablet or capsule with enhanced bioavailability and processes for preparing them are also disclosed. The processes include lyophilisation of the cannabinoid powder or cannabinoid-stilbenoid co-crystals to form a powder which is pressed into tablets. The powder may be generated from the co-crystals of the cannabinoid with pterostilbene or the powder may be formed by subsequently mixing the lyophilized cannabinoid with the stilbenoid before forming the tablet. | 2020-12-24 |
20200397745 | COMPOSITION FOR INHIBITING SKIN CELL PROLIFERATION AND/OR ANTI-INFLAMMATION METHOD FOR INHIBITING SKIN CELL PROLIFERATION AND/OR ANTI-INFLAMMATION AND METHOD FOR TREATING SKIN DISEASES AND/OR INFLAMMATORY DISEASES - A composition for inhibiting skin cell proliferation and/or anti-inflammation is provided. The composition for inhibiting skin cell proliferation and/or anti-inflammation includes: apigenin and luteolin, wherein a weight ratio of the apigenin to the luteolin is about 1.5-25:1, or a mole ratio of the apigenin to the luteolin is about 1.5-25:1. Moreover, the apigenin and the luteolin have a synergistic effect on inhibiting skin cell proliferation and/or anti-inflammation. | 2020-12-24 |
20200397746 | COMPOSITION FOR AMELIORATING CIRCULATORY SYSTEM DISEASES, COMPRISING TEA EXTRACT WITH VARIED INGREDIENTS CONTENT - The present disclosure relates to a composition for ameliorating a circulatory system disease, which contains a green tea extract with modified ingredient content. According to the present disclosure, it is possible to effectively prevent, ameliorate and treat circulatory system diseases without side effects and, thereby, to greatly help patients with circulatory system diseases and contribute to the development of related industries. | 2020-12-24 |
20200397747 | OSTEOCLAST DIFFERENTIATION INHIBITOR CONTAINING UROLITHIN - An object of the present invention is to provide an effective and highly safe agent for inhibiting osteoclast differentiation, and a food or drink, pharmaceutical, supplement, and cosmetic that produce an osteoclast differentiation-inhibiting effect; and the object is fulfilled by an agent for inhibiting osteoclast differentiation, comprising a urolithin. | 2020-12-24 |
20200397748 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS OR PRECURSORS THEREOF - Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions. | 2020-12-24 |
20200397749 | COMPOSITIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST - Provided are formulations and methods for treating, reversing, or reducing acute cannabinoid overdose, cannabinoid hyperemesis syndrome, or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the acute cannabinoid overdose, cannabinoid hyperemesis syndrome, or symptom(s) thereof. | 2020-12-24 |
20200397750 | TUMESCENT CONTRAVENOM DRUG DELIVERY - A tumescent contravenom solution including: (a) a vasoconstrictor, (b) a physiological crystalloid solution, and (c) optionally a contravenom agent that neutralizes tissue toxic enzymes present in a venom and/or a drug that impairs or paralyzes lymphatic smooth muscle function and impairs lymphatic transport of venom. Also described are methods of treating an envenomation in a subject, and a kit for performing the method of treating an envenomation. | 2020-12-24 |
20200397751 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia - Methods for modulating the levels of glucagon and blood glucose of a mammal are provided. In the subject methods, a positive allosteric modulator of AMPA/kainate receptors is administered to a host. The subject methods find use in applications where it is desired to increase one or both of the glucagon and blood glucose levels in a mammalian host. The subject methods find use in applications where it is desired to decrease the size, or breadth, of the circadian range of blood glucose levels in a mammalian host. The subject methods also find use in applications where it is desired to decrease the frequency, severity, or occurrence of hypoglycemia in a mammalian host. Finally, the subject method finds use in applications where it is desired to decrease the frequency, severity, or occurrence of nocturnal hypoglycemia in a mammalian host, particularly that which occurs in diabetics as a result of therapy with insulins or insulin analogs or other glucose lowering agents, or combinations of such agents. | 2020-12-24 |
20200397752 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS - The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound. | 2020-12-24 |
20200397753 | COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain compositions of a 5-HT | 2020-12-24 |
20200397754 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF REM SLEEP BEHAVIOR DISORDER - The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT | 2020-12-24 |
20200397755 | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO - The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT | 2020-12-24 |
20200397756 | A STABLE PHARMACEUTICAL COMPOSITION OF POORLY SOLUBLE NONSTEROIDAL ANTIANDROGENS - The present invention relates to stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogen drug substances suitable for administration for the treatment of prostate cancer. The present invention particularly relates to stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogen (NSAA) drug substances for desirable pharmacokinetic and better patient compliance. | 2020-12-24 |
20200397757 | CYCLOCREATINE PHOSPHATE: A NOVEL BIOENERGETIC THERAPY TO PREVENT AND TREAT ISCHEMIA-INDUCED AND AGING-RELATED CARDIOVASCULAR AND NEURODEGENERATIVE DISEASES - The present invention provides methods and composition of a novel mechanism using the bioenergetic Cyclocreatine Phosphate as a potent cardioprotective drug by preserving cellular energy source, preventing ischemic injury, rejuvenating organ function, thus, maintaining normal physical activity. Cyclocreatine Phosphate can be used as a new therapeutic approach to prevent disease development and progression, and to treat ischemia-induced diseases in ischemic heart disease patients, including: coronary artery disease, unstable angina, acute myocardial infarction, heart failure, atrial fibrillation, and Takotsubo cardiomyopathy, as well as provides cardioprotection during cardiac procedures and surgeries. The invention further provides methods and composition to prevent and treat aging-related neurodegenerative diseases where hypoxia/ischemia play a key role in the development and progression of the disease. More specifically, the present invention provides Cyclocreatine Phosphate as a new therapeutic approach to prevent disease development and progression, as well as to treat patients with brain ischemia (stroke) and Alzheimer's disease. | 2020-12-24 |
20200397758 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders - Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of Formula I where Ar, R | 2020-12-24 |
20200397759 | HODGKIN LYMPHOMA THERAPY - There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphoma in a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: | 2020-12-24 |
20200397760 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER - This application is directed to inhibitors of RAD51 represented by the following structural formula, | 2020-12-24 |
20200397761 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES - The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone. | 2020-12-24 |
20200397762 | METHODS AND COMPOSITIONS FOR DIAGNOSING, TREATING, AND MONITORING TREATMENT OF SHANK3 DEFICIENCY ASSOCIATED DISORDERS - The invention provides novel methods and compositions for diagnosing, treating, and monitoring treatment of Shank3 (SH3 and multiple ankyrin repeat domains 3) deficiency associated disorders. | 2020-12-24 |
20200397763 | PARENTERAL FORMULATION MATERIALS AND METHODS FOR 40-O-CYCLIC HYDROCARBON ESTERS AND RELATED STRUCTURES - This application relates generally to the field of drug treatment paradigms based on specifically formulated compounds for use in targeted therapy or disease prevention. Specifically, this technology provides for compositions and methods for treating, stabilizing, preventing or delaying disease conditions through administration of highly lipophilic compositions with a globular serum protein in combination with other pharmaceutical compositions. | 2020-12-24 |
20200397764 | VAP-1 INHIBITORS FOR TREATING PAIN - This invention relates to the use of inhibitors of VAP-1/SSAO activity, and pharmaceutical compositions comprising the same, for the treatment of pain; and to a combined preparation comprising an inhibitor of VAP-1/SSAO activity and a steroid, and the use of the combined preparation in medicine, particularly for treatment of pain. | 2020-12-24 |
20200397765 | METHOD FOR IMPROVING OR ENHANCING COGNITION - Disclosed herein are a method for improving cognition in an individual having findings consistent with a cognitive impairment, and a method of enhancing cognition in an individual. The methods include administering a therapeutically effective amount of (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane or a metabolite or a pharmaceutically acceptable salt thereof to the individual. | 2020-12-24 |
20200397766 | POROUS EMBOLIZATION MICROSPHERES COMPRISING DRUGS - The current invention provides a method of forming polymeric microspheres loaded with therapeutic agent, comprising: a. exposing porous polymeric microspheres to an organic solvent comprising a dissolved therapeutic agent thereby creating microspheres loaded with therapeutic agent, b. separating the microspheres loaded with therapeutic agent from the organic solvent, c. washing the microspheres loaded with therapeutic agent with water, and d. drying the washed microspheres. The microspheres are particularly useful in embolization therapy. | 2020-12-24 |
20200397767 | STABLE PHARMACEUTICAL PRODUCT AND VESSEL COMPRISING SODIUM PICOSULFATE, MAGNESIUM OXIDE AND CITRIC ACID - Described herein is a stable oral liquid pharmaceutical product comprising sodium picosulfate, magnesium oxide and citric acid. Particularly, sodium picosulfate is physically separated from magnesium oxide and citric acid prior to dispensing and is mixed at the time of administration. | 2020-12-24 |
20200397768 | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS - Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein. | 2020-12-24 |
20200397769 | STABLE NIMODIPINE PARENTERAL FORMULATION - A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80. | 2020-12-24 |
20200397770 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION - Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker. | 2020-12-24 |
20200397771 | Methods and Compositions for Treating Obesity - The present disclosure is directed to compositions and methods for treating obesity or an inflammatory state present in obese mammals. In general, the methods and compositions disclosed herein utilize previously unrecognized miR regulatory pathways to reduce pro-inflammatory cytokine secretion and promote egress of immune cells from inflammation sites. | 2020-12-24 |
20200397772 | Choline Salt Forms of an HIV Capsid Inhibitor - The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N—((S-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3- (trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus. | 2020-12-24 |
20200397773 | STABLE NIMODIPINE PARENTERAL FORMULATION - A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80. | 2020-12-24 |
20200397774 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS - The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases. | 2020-12-24 |
20200397775 | Atropine Pharmaceutical Compositions - The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives. | 2020-12-24 |
20200397776 | Atropine Pharmaceutical Compositions - The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives. | 2020-12-24 |
20200397777 | PREVENTION AND TREATMENT OF ORGAN FIBROSIS - The disclosure provides a method of treating fibrosis of an organ comprising administering a c-P4H inhibitor to a patient suffering from fibrosis in an organ, to counteract pathological fibrosis. c-P4H inhibitors can be administered via various routes, including in an aerosolized state using a nebulizer, intravenous, intraperitoneal or subcutaneous injection. | 2020-12-24 |
20200397778 | SYNERGISTIC CANCER TREATMENT - Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects. | 2020-12-24 |
20200397779 | Methods for the Administration of Certain VMAT2 Inhibitors - Provided is a method of administering a vesicular monoamine transport 2 (VMAT2) inhibitor to a patient in need thereof, wherein the patient experiences one or more clinically significant parkinson-like signs or symptoms. | 2020-12-24 |
20200397781 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE - Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate. | 2020-12-24 |
20200397782 | SOLID FORMS OF A KYNURENINE-3-MONOOXYGENASE INHIBITOR - Forms of 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid (Compound I) were prepared and characterized in the solid state: | 2020-12-24 |
20200397783 | PREVENTION OF HIV-INFECTION - This invention relates to the use of a parenteral formulation comprising the NNRTI TMC278 for the long term prevention of HIV infection in a subject at risk of being infected by HIV, which comprises the intermittent administration of the said formulation at long time intervals. | 2020-12-24 |
20200397784 | FORMULATIONS OF AZAINDOLE COMPOUNDS - The present invention relates to pharmaceutical compositions, each comprising a multitude of granules that make up an intragranular phase of the composition, wherein the granules are produced by fluid bed granulation and comprise a HCl salt of Compound (1).xH | 2020-12-24 |
20200397785 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE - The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders. | 2020-12-24 |
20200397786 | THERAPEUTIC AGENT FOR LUNG CANCER THAT HAS ACQUIRED EGFR-TKI RESISTANCE - A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent. | 2020-12-24 |
20200397787 | TREATMENT OF HAND ECZEMA - The present invention relates to the treatment of hand eczema. The problem to be solved by the invention is to provide a new pharmaceutical use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile. A therapeutic or preventive agent for hand eczema, containing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile as an active ingredient. | 2020-12-24 |
20200397788 | PAR1 MODULATION TO ALTER MYELINATION - Materials and methods for modulating protease activated receptor 1 (PAR1) activity to alter myelination are provided. | 2020-12-24 |
20200397789 | PHARMACEUTICAL COMPOSITION AND USE FOR APPLYING RIBOCICLIB IN PHOSPHODIESTERASE 4-MEDIATED DISEASE TREATMENT OF PATIENT AND INHIBITION OF PHOSPHODIESTERASE 4 ACTIVITY - The invention provides a pharmaceutical composition for treating phosphodiesterase 4-mediated (PDE4-mediated) disease in a patient and inhibition of phosphodiesterase 4 (PDE4) activity. The pharmaceutical composition includes an effective amount of Ribociclib and a pharmaceutically acceptable carrier. The invention further provides a use of the pharmaceutical composition for treating PDE4-mediated disease in a patient. The application of the pharmaceutical composition of the present invention and use thereof are advantageous for inhibiting of PDE4 activity and thus treating a PDE4-mediated disease. | 2020-12-24 |
20200397790 | Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions - Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and/or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods. | 2020-12-24 |
20200397791 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS - The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual and for the treatment and prevention of recurrence in an HSV seropositive individual. | 2020-12-24 |
20200397792 | NON-VASOCONSTRICTING ENERGY-PROMOTING COMPOSITIONS CONTAINING KETONE BODIES - An energy-promoting composition includes a stimulant component such as caffeine, a vasodilator component, an energy source including an exogenous ketone body component, and optionally a nootropic component. The separate components beneficially and synergistically interact with one another enhances the overall energy-promoting effect of the composition more rapidly and to a greater degree than if one or more of the components are omitted. The energy-promoting composition is also formulated to minimize the crash effect common to stimulants such as energy drinks. | 2020-12-24 |